Message #1 From:
Stock News Bot Date: July 7, 2006 04:52:00 AM
BGES News Bio-Bridge Science to Present at C.E. Unterberg Towbin Emerging Growth Conference
OAK BROOK, Ill.--(BUSINESS WIRE)--July 7, 2006--Bio-Bridge Science, Inc. (OTCBB:BGES) a developer of vaccines with broad preventative and therapeutic applications, is pleased to announce that the Company will be presenting at the 2006 C.E. Unterberg Towbin Emerging Growth Conference, July 11-12, at The Mandarin Oriental Hotel in New York. The presentation, to be given by Dr. Liang Qiao, the Company's Chairman and CEO, is scheduled for Wednesday, July 12 at 3:56 pm (ET). Dr. Liang Qiao will provide a company overview as well as in-depth information regarding the recently completed pre-clinical trials of its Oral HIV Vaccine.
About Bio-Bridge Science:
Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy", acted to expedite the approval of domestically produced HIV Vaccines. Bio-Bridge Science's GMP facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform as the HIV vaccine.
Forward Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information and accompanying notes to financial statements.
